Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately.
While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect.
The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI™. The Company will disclose LEQSELVI™ launch plans in due course of time.
Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name “FEXUCLUE®”. FEXUCLUE®, a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.
Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE®(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.
Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties.
Kirti Ganorkar, CEO of India Business, Sun Pharma, said, “Erosive esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life.'
Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company.
The pharma major’s consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24.
Shares of Sun Pharmaceuticals Industries fell 3.47% to Rs 1,650 on the BSE.